Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - cefapirin sodium - withdrawn form - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - cefapirin sodium - withdrawn form - 1 g/100ml

Egypt - English - EDA (Egyptian Drug Authority)

bristol-myers squibb-usa - injection - 500 mg

Egypt - English - EDA (Egyptian Drug Authority)

bristol-myers squibb-usa - injection - 1 gm

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules, usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintain the effectiveness of

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintai

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules, usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintain the effectiveness of c

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce th

United States - English - NLM (National Library of Medicine)

lupin limited - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintai

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 250 mg in 5 ml - cefadroxil for oral suspension usp is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria a